Cargando…
Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
PURPOSE: Tumor genomic profiling is increasingly used to guide treatment strategy in patients with cancer. We integrated tumor genomic, clinical demographic, and treatment response data to assess how prospective tumor-normal sequencing impacted treatment selection in patients with cervical cancer. E...
Autores principales: | Friedman, Claire F., Ravichandran, Vignesh, Miller, Kathryn, Vanderbilt, Chad, Zhou, Qin, Iasonos, Alexia, Vivek, Malavika, Mishra, Pamela, Leitao, Mario M., Broach, Vance, Sonoda, Yukio, Kyi, Chrisann, Zamarin, Dmitriy, O'Cearbhaill, Roisin E., Konner, Jason, Berger, Michael F., Weigelt, Britta, Momeni Boroujeni, Amir, Park, Kay J., Aghajanian, Carol, Solit, David B., Donoghue, Mark T.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644000/ https://www.ncbi.nlm.nih.gov/pubmed/37643132 http://dx.doi.org/10.1158/1078-0432.CCR-23-1078 |
Ejemplares similares
-
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
por: Kyi, Chrisann, et al.
Publicado: (2021) -
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019) -
Pattern of disease and response to pembrolizumab in recurrent cervical cancer
por: Miller, Kathryn M., et al.
Publicado: (2021) -
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023) -
Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines
por: Praiss, Aaron, et al.
Publicado: (2022)